Roche Holding AG

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Public

Established: 1896-01-15

Employees: 103.6K

Market Cap: $270.5B

Website: http://www.roche.com

Introduction: Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.

Clinical Trials

A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)

Phase 3

Terminated

Conditions: Metastatic Breast Cancer

Interventions: Drug: Trastuzumab Emtansine
Other: Placebo
Drug: Atezolizumab

First Posted Date: 2021-02-05

Last Posted Date: 2025-02-17

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 96

Registration Number: NCT04740918

Locations: 🇹🇷
Bakirkoy Dr. Sadi Konuk Egitim ve Arastirma Hastanesi, Tibbi Onkoloji, Bakirkoy / Istanbul, Turkey
🇹🇷
Acibadem University School of Medicine Altunizade Hospital Oncology Service, Istanbul, Turkey
🇹🇷
Kayseri Acibadem Hospital, Kayseri, Turkey

and more 47 locations

A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion

Phase 3

Completed

Conditions: Central Retinal Vein Occlusion
Hemiretinal Vein Occlusion
Macular Edema

Interventions: Drug: Faricimab
Drug: Aflibercept
Procedure: Sham Procedure

First Posted Date: 2021-02-05

Last Posted Date: 2024-08-06

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 729

Registration Number: NCT04740931

Locations: 🇺🇸
Fort Lauderdale Eye Institute, Plantation, Florida, United States
🇺🇸
Assoc Retinal Consultants PC, Royal Oak, Michigan, United States
🇺🇸
Midwest Vision Research Foundation, Chesterfield, Missouri, United States

and more 191 locations

A Study of Atezolizumab in Combination With Bevacizumab in Spanish Patients With Unresectable or Unsuitable for Locoregional Treatments Hepatocellular Carcinoma Not Previously Treated With Systemic Therapy

Phase 3

Terminated

Conditions: Carcinoma, Hepatocellular

Interventions: Drug: Atezolizumab
Drug: Bevacizumab

First Posted Date: 2021-02-01

Last Posted Date: 2025-05-08

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 100

Registration Number: NCT04732286

Locations: 🇪🇸
Hospital Universitario Reina Sofia, Cordoba, Spain
🇪🇸
Complejo Hospitalario de Jaen-Hospital Universitario Medico Quirurgico, Jaen, Spain
🇪🇸
Hospital Lucus Augusti, Lugo, Spain

and more 22 locations

Mass Balance and Absolute Bioavailability Study of RO7049389 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: [13C] RO7049389
Drug: [12C] RO7049389
Drug: [14C] RO7049389

First Posted Date: 2021-01-28

Last Posted Date: 2024-07-15

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 22

Registration Number: NCT04729309

Locations: 🇬🇧
Quotient Sciences, Nottingham, United Kingdom

Bioavailability and Bioequivalence of Two Risdiplam Tablets in Healthy Participants

Phase 1

Completed

Conditions: Muscular Atrophy, Spinal

Interventions: Drug: risdiplam
Drug: omeprazole

First Posted Date: 2021-01-22

Last Posted Date: 2023-03-13

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 131

Registration Number: NCT04718181

Locations: 🇺🇸
Dallas Clinical Research Unit, Dallas, Texas, United States
🇺🇸
Daytona Beach Clinical Rsch Unit, Daytona Beach, Florida, United States
🇺🇸
Covance Clinical Research Unit, Inc, Madison, Wisconsin, United States

and more 1 locations

A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma

Phase 3

Active, not recruiting

Conditions: Relapsed or Refractory Follicular Lymphoma

Interventions: Drug: Mosunetuzumab
Drug: Lenalidomide
Drug: Rituximab
Drug: Tociluzumab

First Posted Date: 2021-01-15

Last Posted Date: 2025-04-16

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 478

Registration Number: NCT04712097

Locations: 🇧🇷
ICTR Curitiba, Curitiba, Paraná, Brazil
🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
🇫🇷
Centre Hospitalier de La Cote Basque, Bayonne, France

and more 110 locations

A Study of TACE Combined With Atezolizumab Plus Bevacizumab or TACE Alone in Patients With Untreated Heaptocellular Carcionma

Phase 3

Active, not recruiting

Conditions: Hepatocellular Carcinoma

Interventions: Drug: Atezolizumab
Drug: Becavizumab
Device: Transarterial chemoembolization (TACE)

First Posted Date: 2021-01-15

Last Posted Date: 2025-05-06

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 342

Registration Number: NCT04712643

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, China
🇯🇵
Kurume University Hospital, Fukuoka, Japan
🇯🇵
Hiroshima University Hospital, Hiroshima, Japan

and more 37 locations

Study to Evaluate the Effects of AT-527 in Non-Hospitalized Adult Patients With Mild or Moderate COVID-19

Phase 2

Completed

Conditions: COVID-19

Interventions: Drug: Placebo
Drug: AT-527

First Posted Date: 2021-01-14

Last Posted Date: 2022-10-26

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 104

Registration Number: NCT04709835

Locations: 🇱🇻
The Family Physician's Practice of Dr. Maija Kozlovska, Salaspils, Latvia
🇨🇦
Hamilton Medical Research Group, Hamilton, Ontario, Canada
🇮🇪
Connolly Hospital, Dublin, Ireland

and more 9 locations

A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer

Phase 2

Completed

Conditions: Biliary Tract Cancer

Interventions: Drug: Atezolizumab
Other: Placebo
Drug: Bevacizumab
Drug: Cisplatin
Drug: Gemcitabine

First Posted Date: 2020-12-21

Last Posted Date: 2024-07-03

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 162

Registration Number: NCT04677504

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Duke Cancer Center, Durham, North Carolina, United States
🇺🇸
City of Hope Cancer Center, Duarte, California, United States

and more 46 locations

Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer

Phase 3

Active, not recruiting

Conditions: Small Cell Lung Carcinoma

Interventions: Drug: Tiragolumab
Drug: Atezolizumab
Drug: Carboplatin
Drug: Tiragolumab Matching Placebo
Drug: Etoposide

First Posted Date: 2020-12-14

Last Posted Date: 2025-04-10

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 123

Registration Number: NCT04665856

Locations: 🇨🇳
Beijing Chest Hospital, Beijing, China
🇨🇳
Zhejiang Cancer Hospital, Hangzhou, China
🇨🇳
Beijing Cancer Hospital, Beijing, China

and more 13 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy